Actinium Pharmaceuticals, Inc.
ATNM · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $81 | $1,030 | $1,144 |
| % Growth | -100% | -92.1% | -10% | – |
| Cost of Goods Sold | $811 | $0 | $0 | $524 |
| Gross Profit | -$811 | $81 | $1,030 | $620 |
| % Margin | – | 100% | 100% | 54.2% |
| R&D Expenses | $30,045 | $38,670 | $23,135 | $17,507 |
| G&A Expenses | $12,076 | $13,331 | $11,999 | $0 |
| SG&A Expenses | $12,076 | $13,331 | $11,999 | $8,077 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$811 | $0 | $0 | $0 |
| Operating Expenses | $41,310 | $52,001 | $35,134 | $25,584 |
| Operating Income | -$42,121 | -$51,920 | -$34,104 | -$24,964 |
| % Margin | – | -64,098.8% | -3,311.1% | -2,182.2% |
| Other Income/Exp. Net | $3,878 | $3,102 | $1,087 | $190 |
| Pre-Tax Income | -$38,243 | -$48,818 | -$33,017 | -$24,774 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$38,243 | -$48,818 | -$33,017 | -$24,774 |
| % Margin | – | -60,269.1% | -3,205.5% | -2,165.6% |
| EPS | -1.27 | -1.83 | -1.37 | -1.2 |
| % Growth | 30.6% | -33.6% | -14.2% | – |
| EPS Diluted | -1.27 | -1.83 | -1.37 | -1.2 |
| Weighted Avg Shares Out | 30,070 | 26,604 | 24,142 | 20,568 |
| Weighted Avg Shares Out Dil | 30,070 | 26,604 | 24,142 | 20,568 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,878 | $3,102 | $1,087 | $190 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $811 | $790 | $699 | $524 |
| EBITDA | -$37,432 | -$51,130 | -$33,405 | -$24,250 |
| % Margin | – | -63,123.5% | -3,243.2% | -2,119.8% |